Last Updated: August 2020

Patient Derived Xenograft (PDX) protocols at The Jackson Laboratory

Frequently Asked Questions (FAQ)

How are PDX models generated at The Jackson Laboratory (JAX)?

What Quality Control Procedures are in place?

The PDX models in the JAX PDX Resource are subject to the following Quality Control (QC) validation steps:
  1. The histology of the engrafted tumor retains morphologic features of the primary patient tumor as determined by a Board Certified pathologist.
  2. Immunohistochemistry (IHC) for human Ki67 validates that the engrafted tumor cells are actively dividing and are of human origin.
  3. IHC for CD45 and cytokeratin (AE1/AE3) rules out a xenograft-associated lymphocytic tumor.
  4. Simple Tandem Repeat (STR) analysis validates provenance of engrafted tumor.

How are cohorts of tumor bearing mice established for dosing studies?

What is the protocol for dosing and measuring drug response in PDX models?

How is animal welfare monitored during dosing studies?

What is the procedure for measuring tumor volume?

How are the results of dosing studies represented graphically?

Can I get the software for generating dosing study graphics displayed on the MMHCdb web site?

How do I access data and information about models in the JAX PDX Resource?